Bayer has spent the past several weeks making headlines on the pharmaceutical front — an FDA filing acceptance, a multi-billion-dollar production commitment, a fresh hybrid bond issue. None of it answers the question that matters most to shareholders right now: how the underlying business actually performed between July and September. That answer arrives on November 3, 2026, when the company publishes its third-quarter results.
The Quarter That Anchors Everything
The upcoming report has become the focal point precisely because recent news has been directional rather than definitive. Deutsche Bank Research kept Bayer at “Buy” with a price target of 60 euros on September 29, but analyst Virginie Boucher-Ferte paired that positive rating with a cautious earnings outlook: operating revenue growth of 1.3 percent alongside a 10 percent decline in operating profit. The combination is a reminder that top-line expansion does not automatically translate into a stronger bottom line.
JPMorgan’s Richard Vosser struck a similar note of caution from a different angle. On October 1, he maintained an “Overweight” rating and a 61-euro target, while warning that early market expectations for the third quarter were likely too optimistic. His concern centered on timing effects in the agricultural division. Neither call represented a downgrade or a target cut — both reflected a distinction between a constructive long-term view and the risk of near-term disappointment. The warnings target expectations, not reported figures.
Shares offered a modest counterpoint on Friday, climbing 2.0 percent to close at 43.82 euros. The gain was a positive daily reaction, but it does nothing to pre-empt the earnings check.
Risk Backdrop, Not a Single Trigger
Additional pressure points surfaced in a media report dated October 5. EU member states were said to be holding to temporary glyphosate approvals, while in the US a multi-billion-dollar settlement approval remained pending. A separate proposal would have pharmaceutical manufacturers share in wastewater costs.
No single cause was established for the share-price weakness at that time. These items form a risk backdrop rather than a clear explanation for every price move. The wastewater proposal, in particular, does not yet translate into a decided financial burden.
Should investors sell immediately? Or is it worth buying Bayer?
Pharma Progress: Real, but Not Yet Revenue
On the other side of the ledger sits Bayer’s regulatory progress with finerenone, marketed as Kerendia. The FDA accepted a supplemental application for treating adults with chronic kidney disease without diabetes, backed by positive results from the Phase III FIND-CKD trial. Acceptance is a procedural step, not an approval — a distinction that matters when sizing up the stock. It supports the prospect of a broader label, but it is not a granted expansion of the treatment field.
The company’s planned investment in a new pharmaceutical production site in New Albany, Ohio, operates on an even longer horizon. Bayer has earmarked 2.2 billion US dollars for the project and expects roughly 600 new jobs. The first module is slated to come online in 2031, with a second following in 2034. That timeline places the build-out in a completely different time zone from the November earnings release.
Financing Has Its Own Clock
Bayer has also been active on the funding side. On September 23, the group placed hybrid bonds worth 2 billion euros, split into two tranches with non-call periods of six and nine years. Tying that capital raise directly to the Ohio site would be a stretch — the two moves address different questions, one about expanding production capacity and the other about raising capital.
What Investors Should Actually Watch
The takeaway for shareholders is a clear measuring stick: pipeline and production developments strengthen the longer-term case, while the November 3 report must show how the business genuinely developed and whether the caution about inflated expectations was warranted. The two should not be netted against each other. Positive drug-development news does not substitute for evidence of improved earnings — and the next hard valuation anchor remains the quarterly report itself.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from October 12 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 12.
Bayer: Buy or sell? Read more here...
